Ep 71 - Hear how pulse field ablation programs may revolutionize cardiac ablation treatment

New therapeutic approaches require fresh perspectives, and few perspectives were as fresh as Dr. Steven Mickelsen, the developer of a potentially paradigm shifting cardiac ablation treatment – pulse field ablation. Dr. Mickelsen, a high school dropout turned musician, fell deep enough in love with electrophysiology to go back to school, obtain a medical degree, and put his inclination to tinker to work in developing a new type of ablation. In this podcast we’ll walk down the path that led Dr. Mickelsen to create Farapulse, the early pioneer in this form of energy that now belongs to Boston Scientific. Dr. Mickelsen left the company a few years ago but he’s resumed his work helping Acutus Medical bring their technology to the market. He serves as that company’s chief translational science officer. In our second talk, we connect with Dr. Kenneth Stein, senior vice president and CMO of Boston Scientific’s cardiac rhythm management business. Dr. Stein allows us to pick up where Farapulse is leaving off, explaining why Boston Scientific bought the company now and what the plans are for the ablation systems, which has CE Mark but still requires FDA approval. Dr. Stein also shares advice for those physicians who may want to join a corporation. We also bring in Medtronic’s Rebecca Seidel, president of cardiac Ablation Solutions, and Dr. Robert Kowal, vice president of medical affairs and CMO at the cardiac rhythm and heart failure business. In this excerpt from our recent MedtronicTalks Podcast, Seidel and Dr. Kowal give a quick update on that company’s pulse field ablation technology. This week’s Newmarker’s Newsmakers is delivered by Senior Editor Danielle Kirsh and Associate Editor Sean Whooley including news from Ultrahuman, Johnson & Johnson, ResMed, Abiomed, and Abbott. Subscribe to this podcast on Amazon, Apple, Google and Spotify and other leading podcast apps.

There are no comments yet.

Please log in to write the first comment.